Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) selectively induces apoptosis in transformed cells. Normal cells and certain tumor cells can evade Apo2L/TRAIL induced cell death, but the determinants of Apo2L/TRAIL sensitivity are poorly understood. To better understand the factors that contribute to Apo2L/TRAIL resistance, we characterized two colon carcinoma lines with pronounced differences in Apo2L/TRAIL sensitivity. Colo205 cells are highly sensitive to Apo2L/TRAIL whereas Colo320 cells are unresponsive. Components of the DISC (death inducing signaling complex) could be immunoprecipitated from both cell lines in response to Apo2L/TRAIL. Sensitizing agents including a proteasome inhibitor conferred Apo2L/TRAIL sensitivity in Colo320 cells, indicating that the apoptotic machinery was intact and functional. We specifically suppressed the expression of Bcl-2, FLIP or XIAP in Colo320 cells. Downregulation of either FLIP or XIAP but not Bcl-2 restored sensitivity of Colo320 cells to Apo2L/TRAIL. Moreover, stable knockdown of XIAP expression in Colo320 subcutaneous tumors resulted in suppression of tumor growth and sensitivity to Apo2L/TRAIL in vivo. Our results indicate that only a specific subset of anti-apoptotic proteins can confer resistance to Apo2L/TRAIL in Colo320 cells. Elucidation of the factors that contribute to Apo2L/TRAIL resistance in tumor cells may provide insight into combination therapies with Apo2L/TRAIL in a clinical setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have shown that XIAP can promote resistance of CRC cells to apoptosis induced by multiple tumor treatments [251,252,253].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [252]
Citations
Cites
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900 · cited 1×
“Apo2L/TRAIL is a type II transmembrane protein of the TNF superfamily that was identified based on sequence homology to TNF and Fas ligand (FasL) [1, 2].”
BackgroundInhibition of death receptor signals by cellular FLIP
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,563 · cited 1×
“FLICE inhibitory protein (FLIP) is also recruited to the receptor complex and can act as an inhibitor of caspase 8 when present at high levels [12, 13].”
BackgroundTumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Self-citationSafety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793 · cited 1×
“Apo2L/TRAIL is a type II transmembrane protein of the TNF superfamily that was identified based on sequence homology to TNF and Fas ligand (FasL) [1, 2].”
BackgroundThe Receptor for the Cytotoxic Ligand TRAIL
Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., & Dixit, V. M. (1997) · Science · doi:10.1126/science.276.5309.111 · Cited by 1,767
IAP proteins: blocking the road to death's door
Salvesen, G. S., & Duckett, C. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm830 · Cited by 1,756 · cited 1×
“Smac/DIABLO promotes apoptosis by binding to and neutralizing the inhibitor of apoptosis proteins, or IAPs, which can sequester caspase 3 [18].”
BackgroundControl of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL
Pan, G., Ni, J., Wei, Y.-F., Yu, G.-L., Gentz, R., & Dixit, V. M. (1997) · Science · doi:10.1126/science.277.5327.815 · Cited by 1,496
Strasser, A., O'Connor, L., & Dixit, V. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.217 · Cited by 1,351 · cited 1×
“Malignant cells commonly have defects in cell death control and apoptosis [19].”
BackgroundOsteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
Walczak, H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5386 · Cited by 1,130
Conversion of Bcl-2 to a Bax-like Death Effector by Caspases
Cheng, E. H.-Y., Kirsch, D. G., Clem, R. J., Ravi, R., Kastan, M. B., Bedi, A., Ueno, K., & Hardwick, J. M. (1997) · Science · doi:10.1126/science.278.5345.1966 · Cited by 1,107 · cited 1×
“This is likely a result of caspase mediated FLIP, Bcl-2 and XIAP cleavage as cells undergo apoptosis, as FLIP, Bcl-2 and XIAP are known caspase substrates [28, 29].”
BackgroundKILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,083 · cited 1×
“Proteasome inhibitors can also sensitize cells to Apo2L/TRAIL by transcriptional upregulation of DR5 resulting from stabilization of p53 and the CCAAT/enhancer-binding protein homologous protein (CHOP) [ 48 , 49].”
BackgroundYang, Y., Fang, S., Jensen, J. P., Weissman, A. M., & Ashwell, J. D. (2000) · Science · doi:10.1126/science.288.5467.874 · Cited by 988 · cited 1×
“Proteasome inhibitors can prevent NFkB dependent expression of XIAP and XIAP mediated caspase degradation, yet also block XIAP autoubiquitination and self-degradation, thereby stabilizing its turnover [50, 51].”
BackgroundApo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5
Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., & Ashkenazi, A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80212-5 · Cited by 975
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Sprick, M. R., Weigand, M. A., Rieser, E., Rauch, C. T., Juo, P., Blenis, J., Krammer, P. H., & Walczak, H. (2000) · Immunity · doi:10.1016/s1074-7613(00)80211-3 · Cited by 794 · cited 1×
“sufficient for subsequent activation of the effector caspases 3 and 7, which cleave intracellular substrates to execute cellular apoptosis [ 14 , 15].”
BackgroundDeveraux, Q. L. (1999) · The EMBO Journal · doi:10.1093/emboj/18.19.5242 · Cited by 751 · cited 1×
“This is likely a result of caspase mediated FLIP, Bcl-2 and XIAP cleavage as cells undergo apoptosis, as FLIP, Bcl-2 and XIAP are known caspase substrates [28, 29].”
BackgroundSuzuki, Y., Nakabayashi, Y., & Takahashi, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161506698 · Cited by 654
TRAIL receptor-2 signals apoptosis through FADD and caspase-8
Bodmer, J.-L., Holler, N., Reynard, S., Vinciguerra, P., Schneider, P., Juo, P., Blenis, J., & Tschopp, J. (2000) · Nature Cell Biology · doi:10.1038/35008667 · Cited by 649 · cited 1×
“3 and 7, which cleave intracellular substrates to execute cellular apoptosis [14, 15].”
BackgroundCloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family
Degli-Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J., Huang, C.-P., DuBose, R. F., Goodwin, R. G., & Smith, C. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1165 · Cited by 629
Krueger, A., Schmitz, I., Baumann, S., Krammer, P. H., & Kirchhoff, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101780200 · Cited by 566 · cited 1×
“affect the degree of caspase 8 activation [24, 25].”
BackgroundInsinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., & Pelicci, P. G. (2005) · Nature Medicine · doi:10.1038/nm1160 · Cited by 516 · cited 1×
“Moreover, proteasome inhibitors [36], histone deacetylase inhibitors [37, 38] and cdk inhibitors such as roscovitine [39] can also cooperate with Apo2L/TRAIL to promote apoptosis.”
BackgroundLeBlanc, H., Lawrence, D., Varfolomeev, E., Totpal, K., Morlan, J., Schow, P., Fong, S., Schwall, R., Sinicropi, D., & Ashkenazi, A. (2002) · Nature Medicine · doi:10.1038/nm0302-274 · Cited by 507 · cited 1×
“Truncated Bid interacts with additional pro-apoptotic proteins Bax and Bak, resulting in the release of cytochrome c and Smac/DIABLO from the mitochondria [ 16 , 17].”
BackgroundTRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO
Deng, Y., Lin, Y., & Wu, X. (2002) · Genes & Development · doi:10.1101/gad.949602 · Cited by 458 · cited 1×
“Truncated Bid interacts with additional pro-apoptotic proteins Bax and Bak, resulting in the release of cytochrome c and Smac/DIABLO from the mitochondria [16, 17].”
BackgroundInhibition of TRAIL-induced apoptosis by Bcl-2 overexpression
Fulda, S., Meyer, E., & Debatin, K.-M. (2002) · Oncogene · doi:10.1038/sj.onc.1205258 · Cited by 394
Mitsiades, C. S., Treon, S. P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., Hideshima, T., & Anderson, K. C. (2001) · Blood · doi:10.1182/blood.v98.3.795 · Cited by 392 · cited 2×
“Moreover, proteasome inhibitors [36], histone deacetylase inhibitors [37, 38] and cdk inhibitors such as roscovitine [39] can also cooperate with Apo2L/TRAIL to promote apoptosis.”
BackgroundRegulation of lymphocyte proliferation and death by flip
Thome, M., & Tschopp, J. (2001) · Nature Reviews Immunology · doi:10.1038/35095508 · Cited by 378 · cited 1×
“affect the degree of caspase 8 activation [24, 25].”
BackgroundApoptosis Induction by Caspase-8 Is Amplified through the Mitochondrial Release of Cytochrome c
Kuwana, T., Smith, J. J., Muzio, M., Dixit, V., Newmeyer, D. D., & Kornbluth, S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.26.16589 · Cited by 376 · cited 1×
“some cells, this result argues against Bcl-2 playing an important role in the Apo2L/TRAIL resistance of Colo320 cells [52].”
ResultChawla-Sarkar, M., Bae, S. I., Reu, F. J., Jacobs, B. S., Lindner, D. J., & Borden, E. C. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401416 · Cited by 359 · cited 2×
“Bcl-2 overexpression has been reported to be a mechanism for preventing Apo2L/TRAIL induced apoptosis in several cell lines and siRNA mediated Bcl-2 downregulation has been shown to sensitize resistant melanoma cells to Apo2L/ TRAIL induced apoptosis [40, 41].”
BackgroundDeadly encounter: ubiquitin meets apoptosis
Jesenberger, V., & Jentsch, S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm731 · Cited by 355 · cited 1×
“Interestingly, pro-survival regulators of the Bcl-2 and IAP families are also direct proteasomal targets [46].”
BackgroundTRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL
Screaton, G. R., Mongkolsapaya, J., Xu, X.-N., Cowper, A. E., McMichael, A. J., & Bell, J. I. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00297-1 · Cited by 325 · cited 1×
“Two isoforms of DR5 have been described [8].”
BackgroundDifferential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2
Mérino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., & Micheau, O. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00520-06 · Cited by 305 · cited 1×
“tially co-recruited to DR5 within the DISC, where it inhibits initiator caspase activation [23].”
BackgroundSedger, L. M., Shows, D. M., Blanton, R. A., Peschon, J. J., Goodwin, R. G., Cosman, D. J., & Wiley, S. R. (1999) · PubMed · Cited by 270
Gliniak, B., & Le, T. (1999) · PubMed · Cited by 261
Self-citationFunctional Analysis of TRAIL Receptors Using Monoclonal Antibodies
Griffith, T. S., Rauch, C. T., Smolak, P. J., Waugh, J. Y., Boiani, N., Lynch, D. H., Smith, C. A., Goodwin, R. G., & Kubin, M. Z. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.5.2597 · Cited by 241 · cited 1×
“FACS antibodies: Apo2L/TRAIL R1-M271, Apo2L/TRAIL R2-M413, Apo2L/TRAIL R3-M430 and Apo2L/TRAIL R4-M444 were produced at Amgen Washington and have been described [21].”
MethodFulda, S., Meyer, É., & Debatin, K. (2000) · PubMed · Cited by 237
Nuclear Factor-κB Activation: A Question of Life or Death
Shishodia, S., & Aggarwal, B. B. (2002) · BMB Reports · doi:10.5483/bmbrep.2002.35.1.028 · Cited by 236 · cited 1×
“Since NF-jB transcriptionally regulates many anti-apoptotic genes, including IAP family members, FLIP, Bcl-2, and Bcl-XL, blocking NF-jB can have a profound effect upon cell survival [ 47 ].”
BackgroundSedger, L. M., Shows, D. M., Blanton, R. A., Peschon, J. J., Goodwin, R. G., Cosman, D., & Wiley, S. R. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.2.920 · Cited by 232 · cited 1×
“As all these lines have been generated by infection with lentivirus, we believe this reflects the increased sensitivity of virally infected cells to Apo2L/TRAIL, which has been previously reported [30, 31].”
BackgroundCummins, J. M., Kohli, M., Rago, C., Kinzler, K. W., Vogelstein, B., & Bunz, F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0046 · Cited by 200 · cited 1×
“Other reports have also demonstrated that specific targeting of XIAP or FLIP can restore Apo2L/TRAIL sensitivity [26, 41, 53, 54].”
BackgroundUbiquitin-mediated Degradation of the Proapoptotic Active Form of Bid
Breitschopf, K., Zeiher, A. M., & Dimmeler, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001083200 · Cited by 199 · cited 1×
“Candidate mechanisms include stabilization of pro-apoptotic proteins such as the Bcl-2 family members Bid and Bik [44, 45].”
BackgroundActivation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA
Marsters, S. A., Pitti, R. M., Donahue, C. J., Ruppert, S., Bauer, K. D., & Ashkenazi, A. (1996) · Current Biology · doi:10.1016/s0960-9822(09)00456-4 · Cited by 195
Yoshida, T., Shiraishi, T., Nakata, S., Horinaka, M., Wakada, M., Mizutani, Y., Miki, T., & Sakai, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0693 · Cited by 173 · cited 1×
“Proteasome inhibitors can also sensitize cells to Apo2L/TRAIL by transcriptional upregulation of DR5 resulting from stabilization of p53 and the CCAAT/enhancer-binding protein homologous protein (CHOP) [48, 49].”
BackgroundInducible shRNA expression for application in a prostate cancer mouse model
Czauderna, F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng127 · Cited by 172 · cited 1×
“This method has the advantage of being able to stably knockdown expression of a target gene in > 90% of cells at various stages of tumor development [55].”
MethodMcManus, D. C., Lefebvre, C. A., Cherton-Horvat, G., St-Jean, M., Kandimalla, E. R., Agrawal, S., Morris, S. J., Durkin, J. P., & LaCasse, E. C. (2004) · Oncogene · doi:10.1038/sj.onc.1207967 · Cited by 170 · cited 2×
“Other reports have also demonstrated that specific targeting of XIAP or FLIP can restore Apo2L/TRAIL sensitivity [26, 41, 53, 54].”
BackgroundInsinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V, Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., & Pelicci, P. G. (2005) · Nature Medicine · doi:10.1038/nm0205-233a · Cited by 168
Barry, S. C., Harder, B., Brzezinski, M., Flint, L. Y., Seppen, J., & Osborne, W. R. A. (2001) · Human Gene Therapy · doi:10.1089/104303401750214311 · Cited by 165 · cited 1×
“The lentiviral vector backbone has been described [22].”
Sharp, D. A., Lawrence, D. A., & Ashkenazi, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413962200 · Cited by 153 · cited 4×
“Other reports have also demonstrated that specific targeting of XIAP or FLIP can restore Apo2L/TRAIL sensitivity [26, 41, 53, 54].”
BackgroundInfluentialKim, E. H., Kim, S. U., Shin, D. Y., & Choi, K. S. (2004) · Oncogene · doi:10.1038/sj.onc.1207025 · Cited by 143 · cited 1×
“Moreover, proteasome inhibitors [36], histone deacetylase inhibitors [37, 38] and cdk inhibitors such as roscovitine [39] can also cooperate with Apo2L/TRAIL to promote apoptosis.”
BackgroundMarshansky, V., Wang, X., Bertrand, R., Luo, H., Duguid, W., Chinnadurai, G., Kanaan, N., Vu, M. D., & Wu, J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.3130 · Cited by 119 · cited 1×
“Candidate mechanisms include stabilization of pro-apoptotic proteins such as the Bcl-2 family members Bid and Bik [44, 45].”
BackgroundJin, H., Yang, R., Fong, S., Totpal, K., Lawrence, D., Zheng, Z., Ross, J., Koeppen, H., Schwall, R., & Ashkenazi, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0408 · Cited by 108 · cited 1×
“Tumor cell lines reported to be Apo2L/ TRAIL resistant have been rendered Apo2L/TRAIL sensitive by co-treatment with chemotherapeutic agents such as irinotecan (CPT-11), gemcitabine, 5-FU, taxol and carboplatin [32, 34, 35].”
BackgroundEarel, J. K., VanOosten, R. L., & Griffith, T. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3017 · Cited by 83 · cited 1×
“Moreover, proteasome inhibitors [36], histone deacetylase inhibitors [37, 38 ] and cdk inhibitors such as roscovitine [39] can also cooperate with Apo2L/TRAIL to promote apoptosis.”
BackgroundDifferential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines
van Geelen, C. M. M., de Vries, E. G. E., Le, T. K. P., van Weeghel, R. P., & de Jong, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601065 · Cited by 65 · cited 1×
“Cycloheximide has previously been shown to sensitize cells to death receptor mediated apoptosis and FLIP is at least one protein described to have a high turnover rate and be influenced by cycloheximide treatment [27, 42].”
BackgroundSelf-citationZisman, A., Ng, C., Pantuck, A. J., Bonavida, B., & Belldegrun, A. S. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200111000-00003 · Cited by 57
Brooks, A. D., RAMIREZ, T., Toh, U., Onksen, J. L., Elliott, P. J., Murphy, W. J., & Sayers, T. J. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1339.042 · Cited by 38 · cited 1×
“Proteasome inhibitors have also been shown to either induce apoptosis by themselves or to sensitize cells to apoptotic stimuli, including Apo2L/TRAIL [36, 43].”
BackgroundSträter, J., & Mӧller, P. (2004) · Vitamins and hormones · doi:10.1016/s0083-6729(04)67014-2 · Cited by 32 · cited 1×
“As all these lines have been generated by infection with lentivirus, we believe this reflects the increased sensitivity of virally infected cells to Apo2L/TRAIL, which has been previously reported [30, 31].”
Background
Research works printed but not linked: 1
- Walczak H, Miller RE, Ariail K et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. [see comment]. Nat Med 5:157–163 · DOI · Paper page
Cited by
Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4
Todaro, M., Lombardo, Y., Francipane, M. G., Alea, M. P., Cammareri, P., Iovino, F., Di Stefano, A. B., Di Bernardo, C., Agrusa, A., Condorelli, G., et al. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402305 · Cited by 233
“We and others have found that although the two apoptosisinducing TRAIL receptors are expressed in epithelial cancer cells, including those from colon, breast and lung, their triggering often does not lead to a significant induction of cell death.(32,33) In particular, here, we report that all the epithelial 0 4000 800…”
BackgroundGraves, J. D., Kordich, J. J., Huang, T.-H., Piasecki, J., Bush, T. L., Sullivan, T., Foltz, I. N., Chang, W., Douangpanya, H., Dang, T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.028 · Cited by 169
Self-citationDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Gagnon, V., Themsche, C. V., Turner, S., Leblanc, V., & Asselin, É. (2007) · APOPTOSIS · doi:10.1007/s10495-007-0165-6 · Cited by 128
“We recently reported that XIAP regulates the sensitivity of endometrial carcinoma cell lines to TGF-binduced apoptosis [17]; in other types of cancer cells, XIAP has been shown to be involved in the resistance to death receptors-activating agents, such as TRAIL [26].”
Kaplan-Lefko, P. J., Graves, J. D., Zoog, S. J., Pan, Y., Wall, J., Branstetter, D. G., Moriguchi, J., Coxon, A., Huard, J. N., Xu, R., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.8.11264 · Cited by 126
Self-citation
Metadata
- Authors
- Lippa, M. S., Strockbine, L. D., Le, T. T., Branstetter, D. G., Strathdee, C. A., & Holland, P. M.
- Affiliations
- Amgen (United States) (US)
- Corresponding author
- Holland, Pamela M.
- Venue
- Apoptosis
- Published
- 2007-04-18
- Volume
- 12
- Issue
- 8
- Pages
- 1465-1478
- ISSN
- 1360-8185 (ISSN-L)
- 1573-675X
- OpenAlex
- W2033871520
- Cited by
- 42
- References
- 57
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 1 · 2018: 2 · 2017: 1 · 2016: 3 · 2014: 3 · 2013: 2 · 2012: 4
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- APOPTOSIS (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Keywords
- Apo2L/TRAIL, TRAIL resistance, colon cancer, anti-apoptotic proteins, XIAP, c-FLIP, Bcl-2, death-inducing signaling complex, tumor growth inhibition, combination therapy
- MeSH terms
- Animals, Carcinoma, Colonic Neoplasms, Female, Humans, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Mice, SCID, Apoptosis, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Apoptosis Regulatory Proteins, Mice, X-Linked Inhibitor of Apoptosis Protein, Receptors, Death Domain, TNF-Related Apoptosis-Inducing Ligand, Death Domain Receptor Signaling Adaptor Proteins, CASP8 and FADD-Like Apoptosis Regulating Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.